Clinical study for the relationship between thymoma thymic hyperplasia-related myasthenia gravis and B19 virus infection

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023338

Enrollment

Unknown

Registered

2019-05-23

Start date

2019-07-29

Completion date

Unknown

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myasthenia gravis, thymoma and thymic hyperplasia

Interventions

Myasthenia gravis with thymoma or thymic hyperplasia group:no intervention

Healthy control group:no Intervention

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) It conforms to the diagnostic criteria of myasthenia gravis in Western medicine; (2) Patients with or without thymoma or thymic hyperplasia.

Exclusion criteria

Exclusion criteria: (1) Complicated with tumors other than thymoma; (2) Patients with overlapping systemic lupus erythematosus, Sjogren's syndrome, severe knee osteoarthritis and other autoimmune diseases; (3) Complicated with heart, brain, liver, kidney, lung and other serious diseases. (5) Pregnant or lactating women and psychiatric patients

Design outcomes

Primary

Measure	Time frame
Serum B19 virus antibody;	—

Secondary

Measure	Time frame
Serum B19 virus/EB virus/HSV-2 virus/CMV virus DNA;	—

Countries

China

Contacts

Public ContactZhang Wei

Tangdu Hospital

zhwlyh@fmmu.edu.cn+86 13572570985

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026